RecBio
Taizhou
About RecBio
Recbio, founded in 2012, is an innovative vaccine company based on independent research and development technology. It is dedicated to establishing a full value chain for innovative vaccines, including research and development, manufacturing, and commercialization. The company has always adhered to its mission of "creating first-class vaccines and protecting human health". With a strong R&D engine comprised of novel adjuvants, protein engineering, immunological evaluation, and other core technology platforms, the company is strategically focusing on disease areas with high burdens such as cervical cancers.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 101 – 250
- Estimated revenue: $1K – $10K
- Total funding: $453.5M
- Funding stage: IPO
- Last round: Series C (Jun 2021)
- Ticker: hkg:2179
- Website: recbio.cn
- Phone: 0523-86818860
Industries & Categories
Health Care, Life Science
Social Profiles
Canonical: https://fsome.com/organization/recbio-67016 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.